Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported earnings of ($0.23) per share beating Walls Streets expectations.

ME Staff
-
0

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported Q2 2017 earnings this Afternoon, coming in at ($0.23) per share, beating Wall Street’s estimates of ($0.28) per Share. Revenue for the quarter came in at $3.83 million beating analyst estimates of $1.21 million

Analyst Coverage For Celldex Therapeutics, Inc. (NASDAQ:CLDX)
These are 2 Hold Ratings, 6 Buy Ratings .
The current consensus rating for Celldex Therapeutics, Inc. (NASDAQ:CLDX) is Buy (Score: 2.75) with a consensus target price of $8.08 , a potential (215.76% upside)

Recent Insider Trading for Celldex Therapeutics, Inc. (NASDAQ:CLDX)

  • On 9/2/2016 Tibor Keler, VP, bought 3,000 with an average share price of $3.32 per share and the total transaction amounting to $9,960.00.
  • On 11/23/2015 Avery W. Catlin, CFO, sold 25,000 with an average share price of $18.00 per share and the total transaction amounting to $450,000.00.
  • On 8/25/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $14.00 per share and the total transaction amounting to $70,000.00.
  • On 8/20/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00.
  • On 8/18/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $15.95 per share and the total transaction amounting to $79,750.00.
  • On 8/13/2015 Anthony S Marucci, CEO, bought 5,800 with an average share price of $16.81 per share and the total transaction amounting to $97,498.00.



    Recent Trading for Celldex Therapeutics, Inc. (NASDAQ:CLDX)
    Shares of Celldex Therapeutics, Inc. closed the previous trading session at 2.56 up +0.09 3.64% with 1,113,225 shares trading hands.